FINALITY-HF: CPC Clinical Research / #A randomized, Double-blind, Placebo-controlled Pragmatic Study to Evaluate FINerenone on clinicAL effIcacy and safeTY in Patients with Heart Failure and Reduced Ejection Fraction Who are Intolerant of or Not Eligible

FINALITY HF Sonu Abraham, MD ABSTRACT Medical guidelines in Europe and the US recommend a family of medications called mineralocorticoid receptor antagonists (MRAs) to reduce hospitalization and improve survival in patients with heart failure. Earlier generation MRAs (such as spironolactone or eplerenone) are not suitable for or tolerated by some patients due to their side effect profile (including high potassium levels in the blood, low blood pressure, sexual side effects such as breast tissue development in men, and worsening kidney function). Finerenone is a next generation (newer) MRA drug developed to avoid or minimize these side effects. This study will find out whether finerenone can lower the risk of heart failure and death in participants with heart failure who are unable to take the earlier generation MRAs. Approximately 2600 participants are expected to take part in the study.